Extraordinary Superkines purge tumors and their immunosuppressive ecosystem

Engineered agonist or antagonist versions of interleukin-2 (IL-2), IL-4, or IL-13 successfully stimulate tumor-killing immune cells or disrupt the tumor microenvironment while they synergize with other cancer immunotherapy platforms for potent, targeted treatment.

Like Comment
Page of
Go to the profile of Medicenna

Medicenna

Medicenna is a clinical stage immunooncology company advancing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™. We are developing a unique set of tunable Superkines™ that can be fused with pro-apoptotic proteins to precisely deliver potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment and cancer stem cells without harming healthy cells.

No comments yet.